Refractory and Relapsed
The following is a treatment for patients with refractory and relapsed CLL. For more information, click on the drug name.
- Ibrutinib (ImbruvicaTM)
Some patients still have leukemia cells in their bone marrow after chronic lymphocytic leukemia (CLL) treatment. The term refractory leukemia is used to describe CLL that doesn't result in a remission (but may be stable) or that gets worse within six months of the last treatment. Most people treated for refractory CLL often have good-quality years of remission after more treatment.
However, some patients don't respond to the standard CLL chemotherapy treatment. These include patients whose:
- disease progressed quickly despite treatment
- CLL cells have a deletion in the short arm of chromosome 17 (17p-)
If you fall into either of the above two categories, talk with your doctor about whether taking part in a clinical trial is a option for you. New drug therapies or stem cell transplantation may offer appropriate treatment options.
"Relapsed CLL" is the term for disease that responded to therapy but, after six or more months, stopped responding. Treatment guidelines for people with relapsed CLL are generally the same as treatment for newly diagnosed people. Most people treated for relapsed CLL often have good-quality years of remission after more treatment.